WO1998002568A1 - Bioresolution d'acides n-acylazetidine-2-carboxyliques - Google Patents

Bioresolution d'acides n-acylazetidine-2-carboxyliques Download PDF

Info

Publication number
WO1998002568A1
WO1998002568A1 PCT/GB1997/001916 GB9701916W WO9802568A1 WO 1998002568 A1 WO1998002568 A1 WO 1998002568A1 GB 9701916 W GB9701916 W GB 9701916W WO 9802568 A1 WO9802568 A1 WO 9802568A1
Authority
WO
WIPO (PCT)
Prior art keywords
carboxylic acid
enzyme
acylazetidine
ester
azetidine
Prior art date
Application number
PCT/GB1997/001916
Other languages
English (en)
Inventor
Stephen John Clifford Taylor
Julian Simon Parratt
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Priority to EP97933749A priority Critical patent/EP0912755B1/fr
Priority to DE69722624T priority patent/DE69722624T2/de
Priority to NZ333445A priority patent/NZ333445A/en
Priority to JP50575498A priority patent/JP4189032B2/ja
Priority to US09/202,431 priority patent/US6136591A/en
Priority to AU36995/97A priority patent/AU717771B2/en
Priority to AT97933749T priority patent/ATE242334T1/de
Publication of WO1998002568A1 publication Critical patent/WO1998002568A1/fr
Priority to NO990155A priority patent/NO990155L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • This invention relates to a novel resolution method which is useful in the production of enantiomerically-pure azetidine-2-carboxylic acid, especially enantiomerically-pure (S)-azetidine-2-carboxylic acid.
  • Azetidine-2-carboxylic acid is an unusual amino acid, the (S)-enantiomer of which is known to be useful in the synthesis of inter alia high molecular weight polypeptides, and in particular as an analogue of the well known amino acid proline.
  • Previously documented chiral syntheses of (S)-azetidine-2-carboxylic acid include a five step preparation via homoserine lactone, starting from N- tosyl protected L-methionine (see for example Japanese Patent Application ⁇ ° 14457/74 and Bull. Chem. Soc. Jpn. (1973) 46, 699) and a five step preparation via L-4-amino-2-chlorobutyric acid, starting from L-2,4- dia inobutyric acid (see Biochem. J. (1956) 64, 323).
  • racemic azetidine-2-carboxylic acid obtained via chemical o synthesis inevitably contains contaminants.
  • a resolution procedure which produces only the required single enantiomer, as well as being more economic, is also expected to facilitate chemical purification of the product.
  • Bioresolution is a procedure which is known to be of use generally in the production of enantiomerically-pure compounds.
  • the potential utility and effectiveness of the technique in the resolution of a particular chiral compound is difficult to predict.
  • the process according to the invention there is provided a process for obtaining an enantiomencally ennchedN-acylazet ⁇ d ⁇ ne-2-carboxyhc acid, which process i s compnses the biotransformation of a racemic N-acylazet ⁇ dme-2-carboxyhc acid ester with an enzyme that displays enantiospecificity (hereinafter referred to as "the process according to the invention")
  • enantiomencally ennched when used herein means any mixture 20 of the enantiomers of an N-acylazet ⁇ d ⁇ ne-2-carboxyhc acid in which one enantiomer is present in a greater proportion than the other, for example mixtures with an enantiomenc purity (enantiomenc excess; e.e.) of greater than 50%, preferably at least 70% and more preferably at least 90%.
  • process according to the invention may also be referred to as a process for obtaining an "optically ennched" N-acylazet ⁇ d ⁇ ne-2-carboxyhc acid.
  • the process according to the invention compnses the use of an appropnate 30 enzyme to preferentially hydrolyse one enantiomer of an N-acylazet ⁇ dme-2- carboxylic acid ester to the corresponding acid, which acid may be readily separated from the other, unwanted, enantiomeric ester and from impurities arising from the synthesis ofthe racemic N-acylazetidine-2-carboxylic acid ester. Moreover, the remaining ester may be readily recovered, racemized 5 and re-used in the resolution process.
  • Esters of N-acylazetidine-2-carboxylic acids which may be used in the process according to the invention include aryl (e.g. phenyl) or linear or cyclic alkyl (especially lower alkyl (e.g. C, .6 alkyl)) esters.
  • aryl e.g. phenyl
  • linear or cyclic alkyl especially lower alkyl (e.g. C, .6 alkyl)) esters.
  • lower alkyl e.g. C, .6 alkyl
  • esters which may be mentioned include propyl, ethyl and especially methyl esters of N-acylazetidine-2-carboxylic acids.
  • N-Acyl groups of N-acylazetidine-2-carboxylic acids, and esters, which may be used in the process according to the invention include linear or
  • N-acyl group is an optionally substituted N-benzoyl group, and particularly a N-benzoyl group.
  • the process according to the invention may be carried out in the presence
  • Suitable solvents include water, which may be buffered to a suitable pH using a suitable buffer system including those commonly used in biological systems (e.g. buffers such as Tris, MESm, Bis-Tris, ACES, PIPES, MOPSO) and inorganic buffers such as phosphate buffers.
  • buffers such as Tris, MESm, Bis-Tris, ACES, PIPES, MOPSO
  • inorganic buffers such as phosphate buffers.
  • biotrans formed acid and ester may be separated in accordance with techniques which are well known to those skilled in the art, for example by solvent extraction.
  • N-acyl group of the biotransformed enantiomerically enriched acid may subsequently be removed in order to produce enantiomerically pure azetidine-2-carboxylic acid in accordance with techniques which are well known to those skilled in the art, for example by hydrolysis in the presence of alkali. Saponification may be carried out in this way in aqueous media, at between room temperature and 100°C, in the presence of an appropriate alkali (e.g. an alkali metal hydroxide, such as lithium, sodium or potassium hydroxide).
  • an appropriate alkali e.g. an alkali metal hydroxide, such as lithium, sodium or potassium hydroxide.
  • the process according to the invention may thus be used as part of a process to produce enantiomerically enriched azetidine-2-carboxylic acid.
  • a process for preparing an enantiomerically-pure azetidine-2-carboxylic acid which comprises carrying out a biotransformation as hereinbefore described, followed by deacylation of the resultant enantiomerically enriched N- acylazetidine-2-carboxylic acid.
  • enantiomerically pure azetidine-2-carboxylic acid we mean an enantiomer of azetidine-2-carboxylic acid with an e.e. of greater than 50%.
  • Enantiomeric purity may be further improved (for example to greater than 98%) by crystallisation from an appropriate solvent (e.g. ethyl acetate) which at the same time increases chemical purity.
  • an appropriate solvent e.g. ethyl acetate
  • Racemization of the remaining, non-biotransformed yet enantiomerically enriched, ester may take place by treatment with an appropriate base (e.g. sodium methoxide) in the presence of an appropriate solvent (e.g. methanol) at, for example, between 20 and 100°C (depending on the solvent employed).
  • an appropriate base e.g. sodium methoxide
  • an appropriate solvent e.g. methanol
  • the re-racemized ester may subsequently be re-used in the process according to the invention.
  • the process according to the invention may be used, in conjunction with a deacylation step, to produce enantiomerically pure (R)- or enantiomerically pure (S)-azetidine-2- carboxylic acid.
  • a deacylation step to produce enantiomerically pure (R)- or enantiomerically pure (S)-azetidine-2- carboxylic acid.
  • the process according to the invention is used in the production of the latter, and that the enzyme has enantiospecificity for the (S)-ester.
  • Enzymes for use in the process according to the invention may be used in the presence of the organism from which it originates or in an isolated form.
  • the enzyme may be immobilised if desired.
  • the selection of a suitable enzyme system may proceed by way of a suitable protocol comprising the attempted biotransformation of a racemic N-acylazetidine-2-carboxylic acid ester in the presence of a test enzyme, for example as described hereinafter.
  • the term "attempted biotransformation" when used herein means providing a racemic N-acylazetidine-2-carboxylic acid ester in the presence of a suitable quantity of test enzyme, and determining whether or not an enantiomerically enriched N-acylazetidine-2-carboxylic acid (as defined hereinbefore) is formed. Resolution conditions may be varied as described hereinbefore and the enantiomeric purity of the product determined in accordance with techniques which are well known to those skilled in the art, such as those described hereinafter.
  • suitable enzymes for use in the process according to the invention include those with properties characteristic of (and/or having the same enzymatic activity as) Candida antarctica lipase and Aspergillus tamarii esterase. We have found that such enzymes preferentially hydrolyse the (S)-ester to the (S)-acid, which may be easily separated from the unwanted (R)-ester by extraction, and subsequently saponified as hereinbefore described.
  • Enzymes with properties characteristic of an enzyme from an organism we are including enzymes which originate both directly and indirectly from the original organism, for example enzymes which are expressed from the relevant gene in a suitable heterologous host organism.
  • an alternative route to the production of (S)-azetidine-2-carboxylic acid from racemic N- acylazetidine-2-carboxylic acid ester may involve the enzymatic production of (R)- ⁇ -acylazetidine-2-carboxylic acid using an appropriately enantiospecific enzyme (leaving the (S)-ester unconverted), followed by separation as indicated above.
  • the (R)-azetidine-2-carboxylic acid may then be racemized and esterified, in either order, to provide further racemic substrate.
  • ester and N-acyl groups of the (S)-ester may subsequently be removed in accordance with conventional procedures, in one or two steps, in order to produce to (S)-azetidine-2-carboxylic acid.
  • this procedure is less preferred than the direct enzymatic hydrolysis of the (S)-ester to the (S)-acid.
  • the process according to the invention has the advantages that, unlike the chemical methods described hereinbefore, it avoids the need to handle stoichiometric amounts of resolving agents or auxiliaries; the products from the biotransformation are easily separable; and it provides the materials in a form where the unwanted enantiomer can be readily recycled.
  • the process according to the invention has the advantage that enantiomerically pure azetidine-2-carboxylic acid may be prepared in higher yields, with greater enantiomeric purity, in a manner which involves fewer steps, in less time, more conveniently and at a lower cost than processes previously employed for the production of enantiomerically pure azetidine-2-carboxylic acid.
  • the ester (4.8 g, 21.9 mmol) was stirred in buffer solution (pH 7.5, 50 mM potassium phosphate, 100 mL) at room temperature.
  • buffer solution pH 7.5, 50 mM potassium phosphate, 100 mL
  • Lipase from Candida antarctica (0.48 g; Chirazyme L2; Boehringer Mannheim) was added and the mixture titrated to pH 7.5 using 1M ⁇ aOH.
  • base uptake showed 38% conversion after 3.5 hours, the enzyme was removed by filtration, and the pH adjusted to 8.5 with 5M ⁇ aOH.
  • the ester was extracted with ethyl acetate (300 ml, 5 times), then the combined organic solutions washed with saturated sodium bicarbonate solution (100 ml), brine (100 ml), dried over MgS0 4 , then filtered and evaporated in vacuo to yield a colourless oil (7.72 g, 57% e.e., determined by chiral GC: Chirasil DEX CB column) for racemization.
  • the acid product was recovered by acidification of the biotransformation solution to pH 1.6, followed by extraction with ethyl acetate (200 ml, 4 times).
  • Selected microbial strains with known esterase activity were grown in a medium consisting of an aqueous solution of H 2 P0 4 (7 g/L), K,HP0 4 (2 g/L), (NH 4 ) 2 S0 4 (1 g/L), yeast extract (10 g/L), a trace elements solution ( 1 ml/L) and glucose (10 g/L).
  • the medium was made up at 25 mL per 250 mL Erlenmeyer flask, and was adjusted to pH 6.0 (for fungi and yeasts) and pH 7.0 (for bacteria) prior to sterilisation at 121°C for 20 minutes.
  • the trace elements solution consisted of CaCl 2 .2H 2 0 (3.6 g/L), CoCl 2 .6H,0 (2.4 g/L), CuCl 2 .2H 2 0 (0.85 g/L), FeCl 3 .6H 2 0 (5.4 g/L), H 3 B0 4 (0.3 g/L), HC1 (333 mL (cone. HC1)/L), MnCl 2 .4H,0 (2.0 g/L), Na 2 Mo0 4 .2H 2 0 (4.8 g/L), and ZnO (2.0 g/L).
  • the pH of the samples was adjusted to pH 9.5 with NaOH and extracted into ethyl acetate, dried with Mg 2 S0 4 and injected onto a 25 m, 0.25 mm CHIRASIL DEX CB column. The oven temperature was maintained at 125°C during the analysis. The e.e. of the product was determined by HPLC. The pH of the samples was adjusted to pH 9.5 with NaOH and extracted four times into ethyl acetate to remove the ester. The pH was then adjusted to 1.5 with H,P0 4 and the product extracted into ethyl acetate, dried with Mg 2 S0 4 , and 20 ⁇ L injected onto a 25 cm Chiralcel OD column.
  • the elution buffer was 92:8: 1 heptane:propan-2-ol:trifluoroacetic acid.
  • the flow rate was 1.0 mL.min "1 and detection was at 254 nm.
  • one, Aspergillus tamarii - CMC 3242 in the initial screen achieved 30% conversion of the added substrate after 48 hours biotransformation.
  • the residual ester was shown to be the (R)-enantiomer with a e.e. in excess of 99% and the product to be the (S)-enantiomer with an e.e. in excess of 74%.
  • the Aspergillus tamarii - CMC 3242 strain was deposited on 8 July 1997 at the International Mycological Institute (Egham, UK), under the terms of the Budapest treaty, and has been given the accession number IMI 375930.
  • a culture of Aspergillus tamarii was spread plated onto a PDA plate (39 g/L potato dextrose agar (Oxoid CM139) sterilised at 121°C for 20 minutes, cooled to 50°C and poured into 140 mm petri dishes) and incubated at 25°C for 7 days.
  • the spores of Aspergillus tamarii were then resuspended in sterile (sterilised at 121°C for 20 minutes) 10% w/v glycerol + 0.1% w/v Tween 80.
  • 1 L samples were aliquoted into 2 mL cryovials and stored at -80°C.
  • the following medium was used in the fermenters: KH 2 P0 4 (7 g/L), K 2 HP0 4 (2 g/L), (NH 4 ) 2 S0 4 ( 1 g/L), MgS0 4 .7H 2 0 (1 g/L), Trace elements solution (1 mL/L), polypropylene glycol (1 mL/L), yeast extract (20 g/L), and sucrose (20 g/L).
  • the media was made up to a final volume of 1.5 L per fermenter and the pH adjusted to 6.0 prior to sterilisation (60 minutes at 121°C).
  • the sucrose was sterilised separately as a 50% w/v solution and added to the fermenter after cooling.
  • the fermenter was inoculated with the 1 mL of the spore suspension.
  • the temperature was maintained at 25°C and pH controlled between 5.8 and 6.2. Agitation was 1000 rpm and air flow set at 1.0 L/min.
  • a feed of 100 mL 34% w/v sucrose, + 100 mL 34% w/v yeast extract, + 1.7 g/L (NH 4 ) 2 S0 4 (sterilised separately at 121 °C for 60 minutes) was added to the fermenters after 48 hours.
  • the fermenters were harvested after 72 hours growth by filtration and stored as a cell paste at -20°C.
  • Frozen cell paste (50 g) was thawed in 200 mL 0.1M ⁇ a 2 HP0 4 / ⁇ aH,P0 4 buffer, pH 6.4. The cells were disrupted using a mortar and pestle. 100 g of racemic N-benzoylazetidine-2-carboxylic acid methyl ester was added to the reaction and the volume made up to 1000 mL with 200 mL 0.1M ⁇ a 2 HP0 4 / ⁇ aH 2 P0 4 buffer, pH 6.4. The reaction was run at 25°C and pH controlled at 6.4. A further 50 g of cells was added after 4.5 hours. After 12 hours, the biotransformation broth was filtered through a Celite pad.
  • the salt was removed by suction filtration and the ethanolic solution evaporated to dryness, yielding a white solid (1.85 g, 47% yield).
  • the isolate was re-dissolved in water (100 mL) and neutralised by stirring with Amberlite IRA-67 ion exchange resin (5 g) for 30 minutes (to pH 7.1). The resin was removed by suction filtration and the filtrate evaporated to dryness, yielding a slightly off-white solid ( 1.38 g; quantitative yield).
  • the off-white solid was slurried with refluxing MeOH ( 10 mL) for 5 minutes, allowed to cool to room temperature and the purified product collected by suction filtration (905 mg; 31% yield; 98% e.e.). 'H NMR (D 2 0) was consistent with the structure of the product.

Abstract

Procédé d'obtention d'acides N-acylazétidine-2-carboxyliques à enrichissement énantiomorphe, consistant en la bio-transformation d'un ester racémique d'acides N-acylazétidine-2-carboxyliques avec un enzyme présentant une émantiospécificité.
PCT/GB1997/001916 1996-07-15 1997-07-15 Bioresolution d'acides n-acylazetidine-2-carboxyliques WO1998002568A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP97933749A EP0912755B1 (fr) 1996-07-15 1997-07-15 Bioresolution d'acides n-acylazetidine-2-carboxyliques
DE69722624T DE69722624T2 (de) 1996-07-15 1997-07-15 Die bioauflösung auf n-acylazetidin-2-carbonsäuren
NZ333445A NZ333445A (en) 1996-07-15 1997-07-15 Process for obtaining enantiomerically enriched N-acylazetidine-2-carboxylic acids comprising the biotransformation of racemic N-acylazetidine-2-carboxylic acid ester with an enantiospecific enzyme
JP50575498A JP4189032B2 (ja) 1996-07-15 1997-07-15 Ｎ―アシルアゼチジン―２―カルボン酸の生物学的分割
US09/202,431 US6136591A (en) 1996-07-15 1997-07-15 Bioresolution of N-acylazetidine-2-carboxylic acids
AU36995/97A AU717771B2 (en) 1996-07-15 1997-07-15 The bioresolution of n-acylazetidine-2-carboxylic acids
AT97933749T ATE242334T1 (de) 1996-07-15 1997-07-15 Die bioauflösung auf n-acylazetidin-2- carbonsäuren
NO990155A NO990155L (no) 1996-07-15 1999-01-14 Biooppl°sning av N-acylazetidin-2-karboksylsyrer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9614856.4 1996-07-15
GBGB9614856.4A GB9614856D0 (en) 1996-07-15 1996-07-15 New resolution method

Publications (1)

Publication Number Publication Date
WO1998002568A1 true WO1998002568A1 (fr) 1998-01-22

Family

ID=10796945

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/001916 WO1998002568A1 (fr) 1996-07-15 1997-07-15 Bioresolution d'acides n-acylazetidine-2-carboxyliques

Country Status (11)

Country Link
US (1) US6136591A (fr)
EP (1) EP0912755B1 (fr)
JP (2) JP4189032B2 (fr)
AT (1) ATE242334T1 (fr)
AU (1) AU717771B2 (fr)
CA (1) CA2259402A1 (fr)
DE (1) DE69722624T2 (fr)
GB (1) GB9614856D0 (fr)
NO (1) NO990155L (fr)
NZ (1) NZ333445A (fr)
WO (1) WO1998002568A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004015A1 (fr) * 1997-07-15 1999-01-28 Chirotech Technology Limited Micro-organisme et esterase obtenue a partir de ce micro-organisme
EP0957089A1 (fr) * 1998-05-14 1999-11-17 Sumitomo Chemical Company, Limited Procédé de racémisation d'azétidine-2-carboxylate optiquement actif
EP0974670A2 (fr) * 1998-07-17 2000-01-26 Sumitomo Chemical Company, Limited Procédé de préparation d'un composé optiquement actif de l'acide carboxylique-2-azetidine N-substitué
US6162621A (en) * 1997-01-24 2000-12-19 Sumitomo Chemical Company, Ltd. Process for producing optically active azetidine-2-carboxylic acid derivative
US6313315B1 (en) 1999-06-01 2001-11-06 Sumitomo Chemical Company, Limited Methods for producing N-protected-azetidine-2-carboxylic acids
WO2001092554A1 (fr) * 2000-06-01 2001-12-06 Sk Corporation Procede de fabrication d'acide carboxylique heterocyclique a substitution alpha de forme r ou s, et de forme contre- enantiomere d'acide carboxylique heterocyclique a substitution alpha correspondante, a base d'enzyme
WO2001092553A1 (fr) * 2000-06-01 2001-12-06 Sk Corporation Procede de resolution optique d'un acide carboxylique heterocyclique alpha-substitue racemique a l'aide d'enzymes
KR20030012964A (ko) * 2001-08-06 2003-02-14 주식회사 제노포커스 광학활성 α-치환 헤테로시클릭카르복실산 에스테르의제조방법
US6537790B1 (en) 1999-06-04 2003-03-25 Sumitomo Chemical Company, Limited Esterase genes and uses of the same
US6548680B1 (en) 1998-09-01 2003-04-15 Astrazeneca Ab Process for the production of N-protected azetidine-2-carboxylic acids (azeohs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614856D0 (en) * 1996-07-15 1996-09-04 Chiroscience Ltd New resolution method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000593A1 (fr) * 1992-06-24 1994-01-06 Institut De Recherches Chimiques Et Biologiques Appliquees (I.R.C.E.B.A.) Procede de preparation d'aryl-1 alcanols substitues optiquement purs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614856D0 (en) * 1996-07-15 1996-09-04 Chiroscience Ltd New resolution method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000593A1 (fr) * 1992-06-24 1994-01-06 Institut De Recherches Chimiques Et Biologiques Appliquees (I.R.C.E.B.A.) Procede de preparation d'aryl-1 alcanols substitues optiquement purs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C.R. JOHNSON ET AL.: "Enzymatic asymmetrization of meso-2-cycloalken-1,4-diols and their diacetates in organic and aqueous media", TETRAHEDRON LETTERS, vol. 33, no. 48, 1992, OXFORD GB, pages 7287 - 7290, XP002027733 *
R.M. RODEBAUGH ET AL.: "Resolution of DL-Azetidine-2-carboxylic acid", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 6, no. 6, 1969, PROVO US, pages 993 - 994, XP002027666 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162621A (en) * 1997-01-24 2000-12-19 Sumitomo Chemical Company, Ltd. Process for producing optically active azetidine-2-carboxylic acid derivative
US6410279B1 (en) 1997-01-24 2002-06-25 Sumitomo Chemical Company, Limited Process for producing optically active azetidine-2-carboxylic acid derivative
WO1999004015A1 (fr) * 1997-07-15 1999-01-28 Chirotech Technology Limited Micro-organisme et esterase obtenue a partir de ce micro-organisme
EP1201653A1 (fr) * 1998-05-14 2002-05-02 Sumitomo Chemical Company, Limited Méthode de racémisation d'azétidine-2-carboxylate optiquement actif
EP0957089A1 (fr) * 1998-05-14 1999-11-17 Sumitomo Chemical Company, Limited Procédé de racémisation d'azétidine-2-carboxylate optiquement actif
US6166224A (en) * 1998-05-14 2000-12-26 Sumitomo Chemical Company, Limited Method for racemization of optically active azetidine-2-carboxylate
EP0974670A2 (fr) * 1998-07-17 2000-01-26 Sumitomo Chemical Company, Limited Procédé de préparation d'un composé optiquement actif de l'acide carboxylique-2-azetidine N-substitué
US6143554A (en) * 1998-07-17 2000-11-07 Sumitomo Chemical Company, Limited Process for producing optically active n-substituted azetidine-2 carboxylic acid compound
EP0974670A3 (fr) * 1998-07-17 2001-11-07 Sumitomo Chemical Company, Limited Procédé de préparation d'un composé optiquement actif de l'acide carboxylique-2-azetidine N-substitué
US6548680B1 (en) 1998-09-01 2003-04-15 Astrazeneca Ab Process for the production of N-protected azetidine-2-carboxylic acids (azeohs)
US6313315B1 (en) 1999-06-01 2001-11-06 Sumitomo Chemical Company, Limited Methods for producing N-protected-azetidine-2-carboxylic acids
US6828129B2 (en) 1999-06-04 2004-12-07 Sumitomo Chemical Company Limited Esterase genes and uses of the same
US6812008B2 (en) 1999-06-04 2004-11-02 Sumitomo Chemical Company, Limited Esterase genes and uses of the same
US6537790B1 (en) 1999-06-04 2003-03-25 Sumitomo Chemical Company, Limited Esterase genes and uses of the same
WO2001092554A1 (fr) * 2000-06-01 2001-12-06 Sk Corporation Procede de fabrication d'acide carboxylique heterocyclique a substitution alpha de forme r ou s, et de forme contre- enantiomere d'acide carboxylique heterocyclique a substitution alpha correspondante, a base d'enzyme
KR100378741B1 (ko) * 2000-06-01 2003-04-07 에스케이 주식회사 효소를 이용하여 R-폼 또는 S-폼의 α-치환 헤테로싸이클릭 카르복실산 및 이와 상반되는 광학특성을 갖는 α-치환 헤테로싸이클릭 카르복실산 에스테르를 제조하는 방법
WO2001092553A1 (fr) * 2000-06-01 2001-12-06 Sk Corporation Procede de resolution optique d'un acide carboxylique heterocyclique alpha-substitue racemique a l'aide d'enzymes
KR20030012964A (ko) * 2001-08-06 2003-02-14 주식회사 제노포커스 광학활성 α-치환 헤테로시클릭카르복실산 에스테르의제조방법

Also Published As

Publication number Publication date
EP0912755A1 (fr) 1999-05-06
GB9614856D0 (en) 1996-09-04
DE69722624D1 (de) 2003-07-10
NZ333445A (en) 2000-06-23
AU717771B2 (en) 2000-03-30
EP0912755B1 (fr) 2003-06-04
JP2009022270A (ja) 2009-02-05
JP4189032B2 (ja) 2008-12-03
NO990155L (no) 1999-03-15
CA2259402A1 (fr) 1998-01-22
US6136591A (en) 2000-10-24
NO990155D0 (no) 1999-01-14
ATE242334T1 (de) 2003-06-15
JP2000515371A (ja) 2000-11-21
DE69722624T2 (de) 2004-04-22
AU3699597A (en) 1998-02-09

Similar Documents

Publication Publication Date Title
JP3703719B2 (ja) １−（４−フルオロフェニル）−３（ｒ）−［３（ｓ）−ヒドロキシ−３−（４−フルオロフェニル）−プロピル）］−４（ｓ）−（４−ヒドロキシフェニル）−２−アゼチジノンの合成に有用なトランス−２−（アルコキシカルボニルエチル）−ラクタムの分割
JP2009022270A (ja) Ｎ−アシルアゼチジン−２−カルボン酸の生物学的分割
JP3794702B2 (ja) キラル−α−第３級カルボン酸エステルの酵素的調製法
US5914263A (en) Enzymatic process for the stereoselective preparation of a hetero-bicyclic alcohol enantiomer
US6156893A (en) Process for the preparation of (1S,4R)- or (1R,4S)- 4-(2-amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1-methanol
HU226141B1 (en) Process for the preparation of amino alcohols and derivatives thereof
EP0528607B1 (fr) Procédé de préparation d'esters de l'acide 3-phényl-glycidiques optiquements actifs
JP3732535B2 (ja) 光学活性α−メチルアルカンジカルボン酸−ω−モノエステル及びその対掌体ジエステルを製造する方法
US6242243B1 (en) Trichosporon sp RRLY-15 (DSM 11829) and its use to prepare S(+)-6-methoxy-methyl-2-naphthalene acetic acid
US5248601A (en) Process for preparing L(-)-carnitine chloride
JPH1014590A (ja) 光学活性２−置換−３−フェニルプロピオン酸及びそのエステルの製造方法
EP1348765B1 (fr) Procédé pour la préparation de dérivés optiquement actifs de l'azabicycloheptanone
JPH1175889A (ja) 光学活性α−トリフルオロメチル乳酸及びその対掌体エステルの製造方法及び精製方法
JPH08507683A (ja) エステラーゼおよびバイオトランスフォーメーションにこれを使用する方法
JP4565672B2 (ja) 光学活性β−シアノイソ酪酸類及びその製造方法
JP3970898B2 (ja) 光学活性α−メチルアルカンジカルボン酸−ω−モノエステル及びその対掌体ジエステルを製造する方法
WO1993004058A1 (fr) Esters de glutarate chiraux, leur resolution et composes de glutaramide derives
JPH0662892A (ja) 光学分割によるインドリン−２−カルボン酸の製造方法
JPH0965891A (ja) 光学活性α−メチルアルカン酸誘導体の製造方法
JP2007202563A (ja) 光学活性α−トリフルオロメチル乳酸及びその対掌体エステルの製造方法及び精製方法
MXPA97001992A (en) Procedure for preparing compounds of trans-3-phenylglicidamide optically acti
FR2700537A1 (fr) 1-Hydroxy-2-alcoxycarbonyl-tétralines optiquement pures, procédé pour leur préparation et leur utilisation comme intermédiaires clés de synthèse.
MXPA01003373A (en) Resolution of trans-2 -(alkoxycarbonylethyl) -lactams useful in the synthesis of 1- (4-fluorophenyl) -3(r) -[3(s) -hydroxy-3 -(4-fluorophenyl) -propyl)]-4(s) -(4-hydroxyphenyl) -2-azetidinone
JPH05336992A (ja) 光学活性ピロリジン類の製造法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09202431

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 333445

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2259402

Country of ref document: CA

Ref country code: CA

Ref document number: 2259402

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997933749

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997933749

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1997933749

Country of ref document: EP